TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02338596

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total hip replacement
Description: 1. Simultaneous bilateral sequential total hip arthroplasties under the same anesthetic.~2. Randomization to treatment with an ultra-short or a convnetional cementless stem was accomplished with use of study numbers in sealed envelope, which were opened in the operating room before the skin incision was made.~3. The pore size was 250㎛. A 28-mm-diameter Biolox forte ceramic femoral head (CeramTec AG, Polchingen, Germany) ) was used in all hips. A cementless cup and a 28mm internal-diameter Biolox forte ceramic liner was used in all hips in both groups.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip replacement
Description: 1. Simultaneous bilateral sequential total hip arthroplasties under the same anesthetic.~2. Randomization to treatment with an ultra-short or a convnetional cementless stem was accomplished with use of study numbers in sealed envelope, which were opened in the operating room before the skin incision was made.~3. The pore size was 250㎛. A 28-mm-diameter Biolox forte ceramic femoral head (CeramTec AG, Polchingen, Germany) ) was used in all hips. A cementless cup and a 28mm internal-diameter Biolox forte ceramic liner was used in all hips in both groups.
Study: NCT01392105

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal stem cell
Description: Route : intracoronary injection Frequency : single dose of autologous bone-marrow derived mesenchymal stem cells Dosage : 1x1000000 cells/kg Duration : mean injection duration approximately 4 weeks after primary percutaneous coronary intervention

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: No additional treatment of mesenchymal stem cells
Study: NCT03308071

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Hypnotic induction, relaxation, and guided imagery specific to perioperative symptoms will be administered.
Study: NCT00897832

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Using material that is already being acquired as a component of clinical care (only that which is excess after routine clinical care), it will be determined if pre-treatment markers can be used to correlate with clinical outcomes of survival and recurrence. Examples of such markers include studying if the integrity of DNA repair pathway in pancreatic cancers, analyzed by Rad51 and phosphorylated DNA-PK foci formation, correlates with tumor response to radiotherapy, chemotherapy, and overall survival.
Study: NCT02043678

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo (normal saline)
Description: Intravenous injection ( IV-slow bolus), every 4 weeks for 6 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abiraterone
Description: 1000 mg once daily, oral, with best supportive care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: 1000 mg once daily, oral, with best supportive care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone/Prednisolone
Description: 5 mg twice daily, oral, with best supportive care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone/Prednisolone
Description: 5 mg twice daily, oral, with best supportive care
Study: NCT01543529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917838
Description: Single dose of RO4917838

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RO4917838
Description: Single dose of RO4917838

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to RO4917838
Description: Single dose of placebo to RO4917838

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to RO4917838
Description: Single dose of placebo to RO4917838

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Standard alcoholic drink

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol
Description: Standard alcoholic drink
Study: NCT02202382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng, Varicocelectomy
Study: NCT02118584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrolizumab
Description: Participants will receive etrolizumab 105 milligrams (mg), administered subcutaneously (SC) every 4 weeks for up to 9 years or until either commercial availability or the Sponsor's decision to terminate the study.
Study: NCT02202382

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Korean Red Ginseng, Varicocelectomy
Study: NCT02156076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-919373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-919373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-919373

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Matching with BMS-919373)
Study: NCT02327832

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous BMSCs
Description: Cultured autologous bone marrow-derived mesenchymal stem cells
Study: NCT02202382

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo were provided by Korean Ginseng Corporation (Daejeon, Korea). The placebo capsules were identical in shape, color, and taste.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo were provided by Korean Ginseng Corporation (Daejeon, Korea). The placebo capsules were identical in shape, color, and taste.
Study: NCT02327832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bone marrow-derived mesenchymal stem cells
Study: NCT02202382

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Varicocelectomy
Description: Surgical microscope-assisted varicocelectomy using the subinguinal approach was conducted by a single surgeon.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Varicocelectomy
Description: Surgical microscope-assisted varicocelectomy using the subinguinal approach was conducted by a single surgeon.
Study: NCT03231930

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OraQuick HCV Ab test
Description: The OraQuick HCV point of care test involves the collection of oral fluid and provides an accurate result in approximately 20 minutes. The test involves a clinic nurse or community health worker providing pre-test counselling, then providing an oral swab to study participants, then reading the result and counselling the participant about their HCV antibody test result.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xpert HCV viral load test
Description: The Cepheid Xpert HCV RNA test (Xpert® HCV Viral Load test) is a reverse transcriptase polymerase-based chain reaction amplification technology (RT-PCR) and provides an accurate HCV RNA load within 2 hours (105 minutes), using a serum sample.~This test will be performed for participants who have a positive OraQuick HCV antibody result.
Study: NCT00609882

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasal CPAP
Description: Infants randomized to the Standard nasal CPAP via bubble or ventilator support at levels of 4-8 cm H2O post extubation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasal CPAP
Description: Infants randomized to the Standard nasal CPAP via bubble or ventilator support at levels of 4-8 cm H2O post extubation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Humidified High Flow Nasal Cannula (HHFNC)
Description: HHFNC

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Humidified High Flow Nasal Cannula (HHFNC)
Description: HHFNC
Study: NCT04681027

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxymorphone hydrochloride (HCl)
Description: Opioid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxymorphone hydrochloride (HCl)
Description: Opioid
Study: NCT03436108

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of Bisphenol in urine
Description: to see level of this material in blood of women

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of Bisphenol in urine
Description: to see level of this material in blood of women
Study: NCT00711893

Intervention type: DEVICE
Intervention: Cognis 100-D, Teligen DR and VR 100 HE
Description: Teligen is an implantable defibrillator for detection and termination of life threatening arrhythmias. Cognis includes in addition to these capabilities cardiac resynchronization therapy for patients having heart failure.
Study: NCT04107376

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Retroviewing endoscopy
Description: The colon is inspected with a new retroviewing endoscope

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Retroviewing endoscopy
Description: The colon is inspected with a new retroviewing endoscope
Study: NCT01489410

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug-Eluting Beads (DEB) with Doxorubicin
Description: One treatment of Drug-Eluting Beads (DEB) with Doxorubicin administered to the liver through a groin puncture site and delivered through the vessels that feed the liver (per standard of care).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipiodol Ethanol Mixture
Description: One treatment of Lipiodol Ethanol Mixture (LEM) is administered to the liver through a groin puncture site and delivered through the vessels that feed the liver (per standard of care).
Study: NCT02411357

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: General information about contraceptive options and referral to contraceptive service providers

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: General information about contraceptive options and referral to contraceptive service providers

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: General information about contraceptive options and referral to contraceptive service providers

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WHO contraception protocol
Description: World Health Organization's contraception protocol

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WHO contraception protocol
Description: World Health Organization's contraception protocol

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives
Description: Financial incentives contingent on follow-up visit attendance
Study: NCT01992042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Description: HMG-CoA reductase inhibitors that lowers cholesterol levels. 40mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimonidazole
Study: NCT01588496

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection
Study: NCT00390182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be given at 1250 mg per meter squared over 2 hours days 1 and 8 of a 21 day cycle for a total of 4 cycles.~Radiation:External Radiation Therapy The total dose would be 19.2 Gy divided over 32 fractions twice a day, on day 1 and day 8 after chemotherapy.~\*\*Radiation is the experimental part of the study.
Study: NCT03433053

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Testing Message Intervention
Description: The Health Belief Model will be utilized as the primary theoretical framework in guiding the development of a tailored HIV testing message for young African American women in this intervention. Two conditions will be developed and compared as outlined below. Condition 1 participants will be exposed to an HIV testing message inclusive of culturally tailored information that addresses both culturally specific barriers and facilitators of HIV testing (as identified in Study 1). The message will be brief (will take less than 3 minutes to present/read).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Condition 2 (generic message) participants will be exposed to a simple HIV educational message only, consisting of HIV statistics for women in the United States, information on how HIV is transmitted, where to get tested, and the benefits of HIV testing. The statistics on HIV and where to get tested will be taken directly from the CDC's website. The message will be brief (will take less than 3 minutes to present/read).
Study: NCT02238522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZEN003365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZEN003365
Study: NCT02621671

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Study: NCT02722733

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF (filgrastim)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytosine arabinoside with G-CSF (filgrastim)
Study: NCT01658722

Intervention type: DRUG
Intervention: Bapineuzumab
Study: NCT01012713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobex Spray
Description: Clobex Spray BID for Weeks 1-4 and weeks 9-12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vectical Ointment
Description: Vectical ointment BID for weeks 5-8 and 9-12

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excimer Laser
Description: Laser treatment for weeks 1-6 study and as needed for patients with less than PASI-75 response thereafter.
Study: NCT02688907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775
Description: Dosage and Schedule : AZD1775 175 mg BID per os every 12 hours (x 6 doses, 3 days) administered days 1-3 the first \& second weeks every 21 days Patients will continue to receive study treatment as described above, until they demonstrate objective disease progression (determined by RECIST 1.1) or they meet any other discontinuation criteria.
Study: NCT03782220

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio tape
Description: The Kinesio taping ( Kinesio Tex Gold, 2in x103.3 ft) was applied to sternocleidomastoid, upper trapezium and levator scapulae muscles by the muscle inhibition technique ( from insertion to origin of a muscle) for experimental group.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Shame tape
Description: For the Shame taping group, a placebo taping method considered to be ineffective ( not from insertion to origin of muscles) with the same material without tension and with the neck in neutral position was used.
Study: NCT03720743

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biodanza
Description: Intervention group received a total of 10 sessions, once a week, over the course of two months. Each session lasted 60 minutes. All sessions began with a 10-minute warm-up period combining music and low-intensity movements as a welcome round, followed individual exercises, in pairs and/or groups, which included dance combined with exercises based on the five lines of Biodanza (vitality, sexuality, creativity, affectivity and transcendence). Finally, a celebration and farewell round of 10 minutes was held. At the end of each session, the participants were asked to share their experiences with the rest of the group.
Study: NCT00437736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APO010
Description: APO010 starting at 2.5 µg/m² IV on D1, D15, D22 and D29 followed by a two-week drug rest.
Study: NCT03903016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro SAR342434
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro SAR342434
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous
Study: NCT01668667

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1838262 600 mg
Description: Drug: GSK1838262 600 mg/day Comparison of 3 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1838262 450 mg
Description: Drug: GSK1838262 450 mg/day Comparison of 3 doses
Study: NCT00286468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin and glyburide
Description: Alogliptin 12.5 mg, tablets, orally, once daily and glyburide for up to 26 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin and glyburide
Description: Alogliptin 25 mg, tablets, orally, once daily and glyburide for up to 26 weeks.
Study: NCT01668667

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1838262 300 mg
Description: Drug: GSK1838262 300 mg/day Comparison of 3 doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK1838262 Placebo match
Description: Drug; GSK1838262 placebo to match 600 mg, 450 mg, 300 mg doses
Study: NCT03373695

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dissolve™
Description: Dissolve™ are to be used in the trial

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SeQuent®Please
Description: SeQuent®Please are to be used in the trial
Study: NCT00286468

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyburide
Description: Alogliptin placebo-matching tablets, orally, once daily and glyburide for up to 26 weeks.
Study: NCT02878343

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Incentives
Description: Daily lottery type incentives tied to achievement of weight loss goals

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Incentives
Description: Daily lottery type incentives tied to achievement of weight loss goals

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Environmental strategies
Description: Individually tailored environmental strategies around food intake and physical activity; automated text/emails sent from study website platform

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Environmental strategies
Description: Individually tailored environmental strategies around food intake and physical activity; automated text/emails sent from study website platform
Study: NCT01124032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate
Description: a capsule containing 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate
Description: a capsule containing 20 mg
Study: NCT02995746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: * On study visit #1 all patients will have a SD-OCT scan and measurement of baseline visual acuity. All patients will receive the 0.7mg dexamethasone intravitreal implant~* Subsequent follow-up visits will be at 1 month, 2 months, 3 months, 4 months, 5 months, and 6 months after intravitreal injection of dexamethasone implant~* Each visit will consist of measurement of visual acuity, intraocular pressure, dilated fundoscopic examination, and SD-OCT scan~* Anticipated duration of the study: 6 months
Study: NCT02633579

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erythromycin lactobionate
Description: intravenous administration of erythromycin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atropine
Description: intravenous administration of atropine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythromycin with atropine
Description: intravenous administration of erythromycin with saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: intravenous administration of saline
Study: NCT00983931

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: A single dose of 0.6 mg colchicine administered alone at 7:15 a.m. on Day 1 after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: A single dose of 100 mg cyclosporine administered with colchicine at 7:15 a.m. on Day 15 after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: A single dose of 0.6 mg colchicine administered with cyclosporine at 7:15 a.m. on Day 15 after an overnight fast of at least 10 hours.
Study: NCT02843477

Intervention type: DEVICE
Intervention: ultrasonographic measurement of corrected flow time in carotid artery
Description: Corrected carotid artery flow time is measured using 10-5 MHz linear probe on a portable ultrasound machine. On the two-dimensional image, the optimal image of the long-axis view is obtained at the left common carotid artery. The sample volume is placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination was performed while the Doppler beams were adjusted to ensure \< 60° of angle for the best signal. Then, cardiac cycle time and carotid flow time is measured. Carotid flow time is measured between the upstroke of the flow tracing and the dicrotic notch, and it is corrected for pulse rate by dividing flow time by the square root of the cardiac cycle time to calculate corrected carotid artery flow time (flow time/√cycle time).
Study: NCT00416234

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoendoscopic Rendez vous
Description: intraoperative ERCP for CBD clearance during laparoscopic cholecystectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: preoperative ERCP and CBD clearance
Description: ERCP and CBD clearance followed by laparoscopic cholecystectomy
Study: NCT01088373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine combined to Lenalidomide
Description: Azacitidine: 75mg/m2/d for 5 days per cycle of 28 days. Lenalidomide: 5mg/day during 14 days for cohort 1. Lenalidomide: 5mg/day during 21 days for cohort 2. Lenalidomide: 10mg/day during 21 days for cohort 3.
Study: NCT03277573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate
Description: Salsalate is a non-acetylated dimer of salicylic acid, and is classified as a non-steroidal anti-inflammatory drug (NSAID). Salsalate has been commercially available in the US as a prescription drug for the relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis, and related rheumatic disorder for decades.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive ingredient
Study: NCT02976701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS1033

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy
Description: Standard therapy which consists of: aspirin enteric-coated tablet 1 x 80 mg and clopidogrel film-coated tablet 1 x 75 mg daily for four weeks will be given to both arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard therapy
Description: Standard therapy which consists of: aspirin enteric-coated tablet 1 x 80 mg and clopidogrel film-coated tablet 1 x 75 mg daily for four weeks will be given to both arms.